Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task

Exclusion Criteria

• •The patient is participating in an interventional study
• •The patient is under safeguard of justice or state guardianship
• •Unweaned from the following medications for at least 5 half-lives prior to inclusion: wake-promoting or psychostimulant drugs (modafinil, methylphenidate, mazindol, amphetamine, pitolisant, solriamfetol, sodium oxybate), neuroleptics, hypnotics, antidepressants, anxiolytics, antiepileptics, budipine, dopamine agonist and antagonist antiemetics (except domperidone), opiates, gabapentin, pregabalin, benzodiazepines, Z-hypnotics (zolpidem and zopiclone), monoamine oxidase inhibitors, catechol-O-methyltransferase or sedative antihistamines.
• •Patients with central nervous system diseases: Parkinson's disease, mild cognitive impairment and dementia, progressive supranuclear palsy, multisystem atrophy, Huntington's chorea, amyotrophic lateral sclerosis, epilepsy, history of head trauma with loss of consciousness.
• •Patients with a malignant neoplastic disease requiring therapeutic treatment in the 12months prior to the screening visit
• •Other medical or psychiatric illnesses (with the exception of depression in he depression group) which, in the investigator's opinion, could interfere with the study.
• •History of suicide attempt (including failed attempt), or suicidal ideation in the past month
• •Chronic alcohol consumption or drug abuse in the previous 6 months
• •Sleep-wake circadian rhythm disorders and presence of sleep insufficiency according to ICSD-3 criteria
• •Pregnant, parturient or breast-feeding women.